Nymox Announces Submission of New Drug Application (NDA) to the FDA for Fexapotide Triflutate

IRVINE, Calif., March 03, 2022 (GLOBE NEWSWIRE) -- Nymox Pharmaceutical Corporation (NASDAQ: NYMX) (the“Company”) is pleased to announce today that it has submitted the Company’s New Drug Application (NDA) to the FDA for...
Source: Drugs.com - New Drug Applications - Category: Drugs & Pharmacology Source Type: news